Valeant Pharmaceuticals Intl Inc (NYSE:VRX) decided to lift its proposal for Obagi Medical Products Inc. OMPI besting Merz Pharma Group’s currently disclosed offer for the specialty pharmaceutical firm.
Valeant now will disburse $24 in cash for each Obagi share, increasing its purchase price to around $420M from $345M.
Valeant decided to purchase Obagi in late March, although Merz on Tuesday publicly released a $22-a-share cash offer, or $385M, declaring it wanted stockholders to have an prospect to benefit from its superior proposal.
Merz declared that it had been occupied in discussions with Obagi on a possible combination and was not made conscious that Obagi was allowing for signing another contract.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock hit highest price at $76.33, beginning with a price of $75.43 and reported decreased -4.64% to the closed at $71.87 with day range of $70.88-$76.33. The total market capitalization remained $21.97 billion, total volume held in the session was 6.16 million shares surprisingly higher than its average volume of 1.34 million shares.
To check the Stocks ups and downs, VRX last week stock price volatility remained 2.79% and month was at 2.02%. VRX generated revenue of 2.97 billion in the following twelve months income of $62.19 million. The Company showed a positive 2.10% in the net profit margin and in addition to in its operating margin which remained 8.13%. Company’s annual sales growth for the past five year was 18.20%.
The VRX past twelve months price to sales ratio was 7.22 and price to cash ratio remained 54.19. As far as if notice on other major contributors of similar sectors have sale ratio and price to cash ratio remained Hospira, Inc. (NYSE:HSP)’s P/S 1.25% P/C 6.62%, Alkermes Plc (NASDAQ:ALKS)’s P/S 5.69% P/C 14.75%, Petmed Express Inc (NASDAQ:PETS)’s P/S 1.15% P/C 5.87%, pSivida Corp. (NASDAQ:PSDV)’s P/S 22.13% P/C 3.35%.
Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Entire Disclaimer Here